All Programs

Use the tool below to view all available Global Cardiology Academy Series

Highlights of the Latest Hypertension Guidelines
Highlights of the Latest Hypertension Guidelines
Cardiology
Highlights of the Latest Hypertension Guidelines
- Clyde W. Yancy, MD
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Heart Matters
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
- Susan Davis
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
CME/CE
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
0.25 credits
- Scott Solomon, MD
0.25 credits
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Cardiology
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
- Ahmad Masri, MD, MS
The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
Cardiology
The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
- Erin Michos
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
Cardiology
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
- Christopher Wong
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
Cardiology
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
- Jung-Sun Kim, MD, PhD
Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial 
Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial 
Cardiology
Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial 
- Lawrence Leiter
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
Nephrology
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Nephrology
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
- Richard E. Pratley, MD
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
Nephrology
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
- prof. Hiddo Heerspink
The LDL-C Gap in Statin-Treated Patients: A Population-Level Problem with Economic Consequences
The LDL-C Gap in Statin-Treated Patients: A Population-Level Problem with Economic Consequences
Heart Matters
The LDL-C Gap in Statin-Treated Patients: A Population-Level Problem with Economic Consequences
PREVENT vs PCE: Refining ASCVD Risk Prediction in Statin-Treated Populations
PREVENT vs PCE: Refining ASCVD Risk Prediction in Statin-Treated Populations
Heart Matters
PREVENT vs PCE: Refining ASCVD Risk Prediction in Statin-Treated Populations
Understanding Preload Deficiency in SLE: A New Look at Fatigue and Exercise Intolerance
Understanding Preload Deficiency in SLE: A New Look at Fatigue and Exercise Intolerance
Living Rheum
Understanding Preload Deficiency in SLE: A New Look at Fatigue and Exercise Intolerance
- Ryan Quigley
- Luigi Adamo, MD, PhD
- Andrea Fava, MD
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
CME/CE
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
0.50 credits
- prof. Hiddo Heerspink
- Peter Rossing, MD, DMSc
- Paola Fioretto, MD
0.50 credits
MinuteCE®
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
1.00 credit 9 episodes
- James Burton, DM, FRCP
- Leonie Kraft, MD
- Lucio Manenti, MD, PhD
- Emilio Sanchez, MD, PhD
1.00 credit 9 episodes

All Programs

Popular

Title

Share on ReachMD

Welcome to Global Cardiology Academy

Welcome to Global
Cardiology Academy